

**BCM-MEDICAL GENETICS LABORATORIES
WHOLE GENOME LABORATORY**

PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bcmgeneticlabs.org

SHIP TO: Medical Genetics Laboratories
Baylor College of Medicine
2450 Holcombe, Grand Blvd. -Receiving Dock
Houston, TX 77021-2024
Phone: 713-798-6555

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

PATIENT INFORMATION	SAMPLE INFORMATION
NAME: _____ <small>LAST NAME FIRST NAME MI</small>	DATE OF COLLECTION: ____ / ____ / ____ <small>MM DD YY</small>
DATE OF BIRTH: ____ / ____ / ____ <small>MM DD YY</small>	HOSPITAL#: _____ ACCESSION#: _____
GENDER (Please select one): <input type="checkbox"/> FEMALE <input type="checkbox"/> MALE <input type="checkbox"/> UNKNOWN	SAMPLE TYPE (Please select one): <input type="checkbox"/> BLOOD (EDTA & NaHep) <input type="checkbox"/> FIBROBLAST <input type="checkbox"/> CORD BLOOD
-OR- PLACE PATIENT STICKER HERE	ETHNIC BACKGROUND (Select all that apply): <input type="checkbox"/> AFRICAN AMERICAN <input type="checkbox"/> ASIAN <input type="checkbox"/> ASHKENAZIC JEWISH <input type="checkbox"/> EUROPEAN CAUCASIAN <input type="checkbox"/> HISPANIC <input type="checkbox"/> NATIVE AMERICAN INDIAN <input type="checkbox"/> OTHER JEWISH <input type="checkbox"/> OTHER (Please specify): _____

REPORTING INFORMATION	ADDITIONAL PROFESSIONAL REPORT RECIPIENTS
PHYSICIAN: _____ INSTITUTION: _____ PHONE: _____ FAX: _____ EMAIL (INTERNATIONAL CLIENT REQUIREMENT): _____	NAME: _____ PHONE: _____ FAX: _____ NAME: _____ PHONE: _____ FAX: _____

Whole Exome Sequencing (WES) plus Chromosomal Microarray Analysis (CMA-Comprehensive) (test code 1530) has two components that will be run CONCURRENTLY and reported separately when each test has been completed. Turnaround time for CMA is 14 days and turnaround time for WES is 15 weeks once financial responsibility has been verified.

NOTE: Per our Cancellation Policy, either of these tests can be cancelled before 5 p.m.(central time) the next business day after the sample is received. Cancellation orders received after that time cannot be honored. Tests will be performed, charged, and reports issued. If concurrent testing is not desired, sequential testing may be ordered under the separate test codes, see website for details.

BIOLOGICAL PARENTS SAMPLES are required for WES interpretation of child. Send 10 cc EDTA and 3-5 cc sodium heparin. Be sure to label parental samples with full name and date of birth - DO NOT LABEL WITH CHILD'S NAME.

8995/1505: **MOTHER** (FULL NAME): _____ DOB: ____ / ____ / ____
LAST NAME FIRST NAME MM DD YY

ASYMPTOMATIC
 SYMPTOMATIC (attach summary of findings)

SAMPLE TYPE: _____ DATE OF COLLECTION: ____ / ____ / ____
MM DD YY

NOT AVAILABLE TO BE SENT LATER*

8995/1505: **FATHER** (FULL NAME): _____ DOB: ____ / ____ / ____
LAST NAME FIRST NAME MM DD YY

ASYMPTOMATIC
 SYMPTOMATIC (attach summary of findings)

SAMPLE TYPE: _____ DATE OF COLLECTION: ____ / ____ / ____
MM DD YY

NOT AVAILABLE TO BE SENT LATER*

1506: OTHER RELATIVE OF PATIENT

Prior to submitting samples from a relative other than the parents, please call the lab at (713) 798-6555 to obtain approval. Must sign other relative testing authorization on consent.

Approval Received from (Name of MGL Lab Genetic Counselor): _____ DATE (MM/DD/YY): _____

Exact Relationship of this individual to the patient: _____ GENDER: FEMALE MALE UNKNOWN

FULL NAME: _____ DOB: ____ / ____ / ____
LAST NAME FIRST NAME MM DD YY

ASYMPTOMATIC
 SYMPTOMATIC (attach summary of findings - REQUIRED)

SAMPLE TYPE: BLOOD SALIVA DATE OF COLLECTION: ____ / ____ / ____
MM DD YY

TO BE SENT LATER*

*If parent/other relative samples are to be sent later, please include copy of this requisition form with those samples. Those samples must be received within 3 weeks after the proband sample is received.

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

NAME: _____ DATE OF BIRTH: ____ / ____ / ____ GENDER (Please select one): FEMALE
LAST NAME FIRST NAME MI MM DD YY MALE
 UNKNOWN

CHECKLIST OF ITEMS TO INCLUDE

- PROBAND SAMPLE (EDTA & NaHep)
- REQUISITION
- INDICATION FOR STUDY CHECK LIST
- SIGNED WES CONSENT FORM
- CLINICAL NOTE/SUMMARY
- PEDIGREE
- MATERNAL SAMPLE (EDTA & NaHep)
- PATERNAL SAMPLE (EDTA & NaHep)
- OTHER RELATIVE'S SAMPLE
(must be approved by Lab before sending)

REQUIRED - INDICATION FOR STUDY

Please provide the following clinical information regarding the patient to be tested. If answering "yes," please provide additional description as appropriate (e.g., percentiles for growth parameters, type of limb abnormality, etc.). Please also submit a clinic note and pedigree if available. This information is needed to facilitate interpretation of whole exome sequencing results. If the laboratory requires additional information, please indicate the health care provider to be contacted:

NAME: _____ PHONE/PAGER #: _____

	YES (Provide Description)	NO	UNKNOWN
Prematurity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Intrauterine growth restriction	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Delayed motor milestones	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Delayed speech	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Developmental regression	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Autism/Autistic spectrum	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Intellectual disability	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hearing loss	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hypotonia	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hypertonia/Spasticity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Seizure disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Ataxia	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Abnormal movements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Dysmorphic features	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Short stature	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tall habitus	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Microcephaly	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Macrocephaly	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hyperextensibility	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Joint contractures	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

NAME: _____ DATE OF BIRTH: ____ / ____ / ____ GENDER (Please select one): FEMALE
LAST NAME FIRST NAME MI MM DD YY MALE
 UNKNOWN

REQUIRED - INDICATION FOR STUDY (CONT.)

	YES (Provide Description)	NO	UNKNOWN
Obesity/Overgrowth	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Failure to thrive	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Structural brain abnormalities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Eye anomalies	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Vision loss	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Congenital heart disease	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Kidney abnormalities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Skeletal abnormalities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Scoliosis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Limb malformation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Skin anomalies	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Genital anomalies	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Organomegaly	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hemihypertrophy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cancer/tumor formation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Family history of similar disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

BCM-MEDICAL GENETICS LABORATORIES WHOLE GENOME LABORATORY

PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bcmgeneticlabs.org

SHIP TO: Medical Genetics Laboratories
Baylor College of Medicine
2450 Holcombe, Grand Blvd. -Receiving Dock
Houston, TX 77021-2024
Phone: 713-798-6555

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

INFORMATION AND CONSENT FOR TESTING

Your physician has advised you (or your child) to undergo the genetic test called the Whole Exome Sequencing test (abbreviated WES). The purpose of this document is to provide information about the test. This information is meant to be used as a supplement to your discussion with a health care professional. If you agree to have the WES test, you will be asked to sign the last page of this document, indicating that you understand the information provided and wish to have testing. You will be given a copy of this document for your records.

Description of the Whole Exome Sequencing Test

The Whole Exome Sequencing test is a highly complex test that is newly developed for the identification of changes in an individual's DNA that are causative or related to their medical concerns. The exome refers to the portion of the human genome that contains functionally important sequences of DNA that direct the body to make proteins essential for the body to function properly. These regions of DNA are referred to as exons. It is known that most of the errors that occur in DNA sequences that then lead to genetic disorders are located in the exons. In contrast to current sequencing tests that analyze one gene or small groups of related genes at a time, the Whole Exome Sequencing test will analyze the important regions of tens of thousands of genes at the same time. Therefore, sequencing of the exome is thought to be an efficient method of analyzing a patient's DNA to discover the genetic cause of diseases or disabilities. However, it is possible that even if the WES identifies the underlying genetic cause for the disorder in your family this information may not help in predicting prognosis or change medical management or treatment of disease.

Indications for Testing

The decision to undergo the Whole Exome Sequencing test is made by you and your physician. In general, the test is used when your medical history and physical exam findings strongly suggest that there is a genetic cause for your medical issues. The test requires 5-10 cc (about 1-2 teaspoon) of whole blood. You should expect that results of the WES test will be sent to your physician in 15 weeks.

Test Reporting

When your exome sequence is compared to a normal reference sequence, many variations or differences are expected to be found. Based on currently available information in the medical literature and in scientific databases, we will decide whether any of these variations are predicted to be causative or related to your medical condition. The WES test results will be reported to your physician in two parts. Your physician will receive a copy of the focused report for your sample.

The focused report will contain results that may explain the cause of your current medical problems. In addition it may also contain information in the following categories:

Medically Actionable

The focused report may also contain information on genes and diseases that are considered medically actionable because they have clear and immediate medical significance to your health or the health of family members, whether or not they relate to your current symptoms. The American College of Medical Genetics (ACMG) have published guidelines for the reporting of these types of medically actionable or incidental findings (PMID: 23788249). These guidelines include a list of genes, which may be updated periodically, that have been determined to be considered medically actionable and therefore laboratories should seek and report pathogenic variants in these genes. In accordance with an update to this policy statement (ACMG.net), there is the option to opt out of receiving pathogenic variants information if identified in the genes listed in ACMG policy statement. It will not be reported on either the focused OR the expanded report. Additionally, the MGL under the direction of the medical director and other faculty members may determine additional genes meet the same criteria to be considered medically actionable and therefore warrant the same reporting as the genes included in the ACMG list. However, if you do not want to receive these additional medically actionable gene results, you may also opt out of this information on the FOCUSED report. However, if the EXPANDED report is requested this information will be included, but will not be labeled as medically actionable. See the FAQ on our website for a list of examples.

Carrier Status and Pharmacogenetic Information

Carrier status for autosomal recessive conditions will include disorders recommended for reproductive screening by professional societies such as ACMG or ACOG (such as cystic fibrosis and Tay-Sachs disease, see FAQ on our website for a complete list). Variants in genes involved in drug metabolism will also be reported. Currently, this is limited to the reporting of pharmacogenetic variants to VKORC1/CYP2C9 (altered warfarin metabolism) and CYP2C19 (altered Plavix metabolism).

See below for options regarding receipt of certain categories of results in the focused report. In addition to the focused report, an expanded report will be available if you and your physician decide to request it.

The patient's sample will have certain findings confirmed by a second methodology (Sanger sequencing) based on the following guidelines.

- Pathogenic or likely pathogenic variants related to patient phenotype will have Sanger confirmation.
- Variants of unclear clinical significance (VUS) related to phenotype with established autosomal dominant inheritance pattern will have Sanger confirmation when at least one parental sample has been received.

BCM-MEDICAL GENETICS LABORATORIES WHOLE GENOME LABORATORY

PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bcmgeneticlabs.org

SHIP TO: Medical Genetics Laboratories
Baylor College of Medicine
2450 Holcombe, Grand Blvd. -Receiving Dock
Houston, TX 77021-2024
Phone: 713-798-6555

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

INFORMATION AND CONSENT FOR TESTING (cont.)

- VUS related to phenotype with established autosomal recessive inheritance will have Sanger sequencing when there are two variant alleles when at least one parental sample has been received.
- VUS related to phenotype with established X-linked inheritance will have Sanger confirmation when at least one appropriate parental sample has been received.
- Medically actionable pathogenic variants and carrier status mutations for autosomal recessive conditions recommended for reproductive screening will have Sanger confirmation.
- As determined by the laboratory, additional confirmation beyond these categories may also be performed.

Once the focused report is received the expanded report can be ordered (no additional charge). The expanded report may contain information on diseases and genes that do not relate to your current condition, or may develop many years from now, or do not have any known link to disease, according to current knowledge. Information included in the expanded report is not Sanger confirmed (unless determined necessary by the laboratory). In discussion with your physician, the expanded report can be ordered for up to 6 months after the focused report is received, for no additional charge. A requisition for ordering the expanded report is available on our website. Please allow 4 weeks for the expanded report. Because medical information continues to advance, it is important to know that the interpretation of the variants is based on information available at the time of testing and may change in the future.

Report Exclusions

The focused and expanded reports will not report findings in genes causing adult onset dementia syndromes for which there is presently no prevention or cure.

Request for Biological Parental Samples

Biological parental samples are requested to facilitate interpretation of WES results. WES will NOT be performed on the parental samples. The parental samples will be tested by other targeted methods for changes in genes that are highly likely to be causative of disease (related to patient indication for testing) to confirm mode of inheritance, de novo status, etc. These studies will be performed at no additional charge. Additionally, carrier status for reproductive screening will also be reported. A separate parental report will not be issued. The laboratory will decide which changes will need parental studies based on the following criteria.

- Using Sanger sequencing parental samples will be tested to determine inheritance in the proband for genes related to patient phenotype.
- Parental samples will not be run for genes with autosomal recessive inheritance pattern that only have one VUS sequence change identified related to patient phenotype.
- We will not report parental data for medically actionable pathological variants identified in the proband (child). If such testing is desired it can likely be completed at a later date, for no additional charge, once consent is given to your provider. Once a test order is received it will take several weeks to complete the additional testing.
- We will report parental data for carrier status recommended for reproductive screening.
- Parental inheritance information will not be included for any of the genes reported in the Expanded report.
- For other biological relatives submitted, Sanger sequencing will be performed only for changes related to the patient phenotype, as described above (Items 1 and 2).

Potential Risks and Discomforts

- (1) It is possible that you could have a mutation in a gene included in the WES test, but the WES test was unable to detect the mutation. Therefore, it is possible that you may be affected with one of the conditions tested by WES, but that the test did not detect the condition.
- (2) The WES test does not analyze 100% of the genes in the human genome. There are some genes that cannot be included in the test due to technical reasons.
- (3) Results may be unclear or indicate the need for further testing on other family members, usually parents. It is possible, that additional information may come to light during these studies regarding family relationships. For example, data may suggest that family relationships are not as reported, such as non-paternity (the father of the individual is not the biological father).
- (4) If you sign the consent form, but you no longer wish to have your sample tested by WES, you can contact your doctor to cancel the test. If testing is complete, but you have not received your results yet, you can inform your doctor that you no longer wish to receive the results. However, if you withdraw consent for testing after 5 p.m. the next business from the day of sample receipt by the laboratory, you will be charged for the full cost of the test.
- (5) The cumulative results of WES testing on many samples may be published in the medical literature. These publications will not include any information that will identify you personally.
- (6) Due to the fact that many different genes and conditions are being analyzed, there is a risk that you will learn genetic information about yourself or your family that is not directly related to the reason for ordering the WES. This information might relate to diseases with symptoms that may develop in the future in yourself or other family members as well as conditions that have no current treatment. If you have concerns about learning about other diseases unrelated to your current medical problems, please tell you doctor so that the results will not include this information.

BCM-MEDICAL GENETICS LABORATORIES
WHOLE GENOME LABORATORY

PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bcmgeneticlabs.org

SHIP TO: Medical Genetics Laboratories
Baylor College of Medicine
2450 Holcombe, Grand Blvd. -Receiving Dock
Houston, TX 77021-2024
Phone: 713-798-6555

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

INFORMATION AND CONSENT FOR TESTING (cont.)

Please read the below statements carefully and check the appropriate box and initial. Please note that if neither box is checked the lab will default to the YES/ reporting option; default for medically actionable, if no choice is selected, is to receive ALL medically actionable findings in the focused report.

Initial 1. Carrier Status for Autosomal Recessive Conditions Recommended for Reproductive Carrier Screening

- YES: please report carrier status. By checking this box, I choose to receive information regarding carrier status.
- NO: please do NOT report carrier status. By checking this box, I choose to NOT receive information regarding carrier status.

2. Pharmacogenetic Variants

- YES: please report genes involved in drug metabolism. By checking this box, I choose to receive information regarding drug metabolism. Currently, this is limited to the reporting of pharmacogenetic variants to VKORC1/CYP2C9 (altered warfarin metabolism) and CYP2C19 (altered Plavix metabolism).
- NO: please do NOT report genes involved in drug metabolism. By checking this box, I choose to NOT receive information regarding drug metabolism.

3. Medically Actionable (3 choices)

- YES/ALL: please ONLY report pathogenic variants in genes included in the ACMG policy statement AND pathogenic variants in genes that the MGL laboratory has determined are medically actionable (defined as having clear and immediate medical significance to your health or the health of family members).
- YES/ACMG ONLY: please ONLY report pathogenic variants in genes included in the ACMG policy statement (defined as having clear and immediate medical significance to your health or the health of family members).
- NO: please do NOT report pathogenic variants in genes included in the ACMG policy statement AND do NOT report pathogenic variants in genes that the MGL laboratory has determined are medically actionable. Pathogenic variants in genes in the ACMG policy statement will not be reported in either the focused or the expanded report. I also chose not to receive information regarding MGL determined medically actionable findings, but if the expanded report is requested this information WILL BE INCLUDED in that report, but will not be labeled as medically actionable.

4. Option to allow release of updated results

We may periodically review old cases when new information is learned regarding the significance of changes in a particular gene. If a possible diagnosis can be made with this information we would like to issue an updated report to the physician who ordered your WES test. The current schedule for this review is every six months, but is subject to change and does NOT include a complete review of all of your data.

- YES: if new information is known regarding clinical significance of information that may not have previously been included in my WES report I would like for you to issue an updated report to my physician who ordered this WES testing.
- NO: please do NOT issue an updated report if there is new information regarding the clinical significance of my WES data that may not have been previously reported.

For Samples Submitted From New York State

Specimen Retention: My sample shall be destroyed at the end of the testing process or not more than 60 days after completion of testing. However, I hereby authorize the lab to retain my sample(s) for a longer retention in accordance to the laboratory retention policy for internal laboratory quality assurance studies and possible research testing.

Initial

**BCM-MEDICAL GENETICS LABORATORIES
WHOLE GENOME LABORATORY**

PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bcmgeneticlabs.org

SHIP TO: Medical Genetics Laboratories
Baylor College of Medicine
2450 Holcombe, Grand Blvd. -Receiving Dock
Houston, TX 77021-2024
Phone: 713-798-6555

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

INFORMATION AND CONSENT FOR TESTING (cont.)

Due to the complex nature of the WES testing it is recommended that families seek genetic counseling in conjunction with testing.

I hereby authorize the BCM Medical Genetics and Whole Genome Sequencing Laboratories to conduct genetic testing for myself (or my child) for the Whole Exome Sequencing test (WES) as recommended by my physician.

Signature: _____ Date: _____

Printed Name: _____

Patient Name: _____ Patient DOB (MM/DD/YY): _____

Relationship to Patient: _____

Physician's/Counselor's Signature: _____ Date: _____

Parental/Other Relative Testing Authorization

I hereby authorize the BCM Medical Genetics and Whole Genome Sequencing Laboratories to conduct genetic testing for myself for the purposes of clarifying results for the Whole Exome Sequencing test (WES) that is being performed on my child's blood sample as recommended by my child's physician. I understand that my sample will not be subjected to WES, but will be subjected to targeted testing methodologies (Sanger sequencing). A separate report of these data will not be issued.

Mother Signature: _____ Date: _____

Printed Name: _____ DOB (MM/DD/YY): _____

Father Signature: _____ Date: _____

Printed Name: _____ DOB (MM/DD/YY): _____

Other Relative's Signature (or Parent/Legal Guardian) for sample submitted: _____

Printed Name: _____ Date: _____

DOB (MM/DD/YY): _____ Relationship to Other Relative's Sample Submitted: _____

SEE NEXT PAGE FOR POTENTIAL RESEARCH OPPORTUNITY

**BCM-MEDICAL GENETICS LABORATORIES
WHOLE GENOME LABORATORY**

PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bcmgeneticlabs.org

SHIP TO: Medical Genetics Laboratories
Baylor College of Medicine
2450 Holcombe, Grand Blvd. -Receiving Dock
Houston, TX 77021-2024
Phone: 713-798-6555

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

Additional Studies- RESEARCH

There may be research studies that you may be eligible for and may be of interest to you. Please read the following statements carefully and check the appropriate box. If the "YES"/contact option is chosen please complete the additional information requested. Please note that if neither box is checked the lab will default to the "NO"/ no contact option.

YES, the BCM Medical Genetics Laboratories may share my contact information with researchers who have a Baylor College of Medicine Institutional Review Board (IRB) approved research study for which I may be eligible for participation. There is no obligation to participate if contacted. No information, other than the contact information below, will be provided to the researcher.

Authorization and contact information MUST be completed, or we will not be able to reach you regarding these opportunities.

Authorization:

Signature: _____ Date: _____

Printed Name: _____

Patient Name: _____ DOB (MM/DD/YY): _____ Relationship to Patient: _____

Contact Information:

Phone #: _____ Alternative Phone #: _____

Address: _____
City _____ State _____ Zip Code _____

E-mail: _____

Preferred method of contact: Email Mail Phone

NO, I DO NOT wish to be contacted regarding participation in research studies.
Initial _____

YES, The BCM Medical Genetics Laboratories may contact my/my child's doctor who ordered the WES test to discuss research studies that I/my child may be eligible for. There is no obligation to participate if contacted. If choosing YES, please make sure that the "Authorization" section above is completed.

PHYSICIAN WHO ORDERED WES - CONTACT INFORMATION:

Last Name: _____ First Name: _____

Phone #: _____ FAX #: _____

Address: _____
City _____ State _____ Zip Code _____

NO, I DO NOT want my/my child's doctor contacted regarding research studies
Initial _____

**BCM-MEDICAL GENETICS LABORATORIES
WHOLE GENOME LABORATORY**

PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bcmgeneticlabs.org

SHIP TO: Medical Genetics Laboratories
Baylor College of Medicine
2450 Holcombe, Grand Blvd. -Receiving Dock
Houston, TX 77021-2024
Phone: 713-798-6555

WHOLE EXOME SEQUENCING PLUS CMA REQUISITION (TEST CODE: 1530)

BILLING INFORMATION

IMPORTANT NOTICE: ONE OF THE THREE FOLLOWING BILLING OPTIONS MUST BE INDICATED BELOW.
PLEASE FORWARD ALL BILLING QUESTIONS TO: MEDGENBILLING@BCM.EDU

PATIENT INFORMATION

PATIENT NAME (LAST, FIRST, MI): _____ PATIENT DATE OF BIRTH (MM/DD/YY): _____
ADDRESS: _____ CITY, STATE, ZIP: _____
PHONE: _____ EMAIL: _____

PAYMENT OPTION 1 - INSTITUTION

BCM-MEDICAL GENETICS LABORATORIES CAN ONLY RUN THIS TEST IF THE INSTITUTION ACCEPTS FINANCIAL RESPONSIBILITY FOR THE FULL PRICE OF THE TEST. PLEASE SIGN AND DATE BELOW THAT YOU ARE AN AGENT OF THE ORDERING INSTITUTION AND CAN ORDER GENETIC TESTING ON ITS BEHALF. TESTING WILL NOT BEGIN WITHOUT THIS SIGNATURE.

PRINTED NAME: _____ SIGNATURE: _____ DATE (MM/YY): _____

INSTITUTION NAME: _____ INSTITUTION CODE: _____
CONTACT NAME: _____ EMAIL (REQUIRED): _____
BILLING ADDRESS: _____ CITY, STATE, ZIP: _____
PHONE: _____ FAX: _____

PAYMENT OPTION 2 - SELF-PAY (PAYMENT MUST ACCOMPANY SAMPLE)

CREDIT CARD (PLEASE SELECT ONE): AMEX DISCOVER MC VISA
VALID CARD #: _____ EXPIRATION DATE (MM/YY): _____ CVC CODE: _____
CARDHOLDER PRINTED NAME: _____ CARDHOLDER SIGNATURE: _____

CHECK/MONEY ORDER

PAYMENT OPTION 3 - INSURANCE

PROVIDE A LEGIBLE PHOTOCOPY OF THE FRONT & BACK OF THE INSURANCE CARD OR HMO/MEDICAID HMO AUTHORIZATION/REFERRAL.

INSURED MEMBER'S INFORMATION

MEMBER NAME (Last, First, MI): _____ MEMBER DATE OF BIRTH (MM/DD/YY): _____ GENDER: FEMALE MALE
MEMBER POLICY #: _____ MEMBER SS #: _____ MEMBER GROUP #: _____
INSURANCE CO. NAME: _____ PHONE: _____
INSURANCE CO. ADDRESS: _____ CITY, STATE, ZIP: _____

ORDERING PROVIDER: _____

ICD9 Diagnosis Code(s) - must be provided or insurance cannot be filed: _____

INSURANCE FINANCIAL POLICY: I UNDERSTAND THAT INSURANCE IS FILED TO BCM-MEDICAL GENETICS LABORATORIES' CONTRACTED CARRIERS AS A CLIENT SERVICE COURTESY. I AM AWARE THAT I AM RESPONSIBLE FOR NON-COVERED SERVICES, DEDUCTIBLES, CO-INSURANCE, CONTRACT EXCLUSIONS, NON-AUTHORIZED SERVICES AND REMAINING BALANCES AFTER INSURANCE REIMBURSEMENT. I AUTHORIZE BCM-MEDICAL GENETICS LABORATORIES TO FURNISH ANY MEDICAL INFORMATION REQUESTED ON MYSELF, OR MY COVERED DEPENDENTS. IN CONSIDERATION OF SERVICES RENDERED, I TRANSFER AND ASSIGN ANY BENEFITS OF INSURANCE TO BCM-MEDICAL GENETICS LABORATORIES.

I have read and agree to all sections of the insurance financial policy above - TESTING WILL NOT BEGIN WITHOUT THIS SIGNATURE

PRINTED NAME: _____ SIGNATURE: _____ DATE (MM/YY): _____